Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kamada Ltd (KMDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
5 Biotech Stocks Under $10 Worthy of Investors' Attention

Small biotech stocks are good bets with lower market cap as well as share price.

MNLO : 8.25 (+1.73%)
SHPG : 158.88 (-1.77%)
CYTR : 1.29 (+3.20%)
KMDA : 5.10 (-0.97%)
BLPH : 2.51 (+2.45%)
SNSS : 2.14 (+1.42%)
SNY : 39.41 (-1.33%)
Results of Kamada's Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association's 78th Scientific Sessions

Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that the results from the Company's Phase 2 trial of Alpha-1 Antitrypsin (AAT) in newly diagnosed type-1...

KMDA : 5.10 (-0.97%)
Kamada Ltd to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Kamada Ltd (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:30 AM Eastern Time.

KMDA : 5.10 (-0.97%)
Kamada Reports Financial Results for First Quarter of 2018

-- U.S. Launch of KEDRAB(R) [Human Rabies Immune Globulin (HRIG)] Represents Significant Company Milestone

KMDA : 5.10 (-0.97%)
Kamada to Announce First Quarter 2018 Financial Results and Host Conference Call on May 15

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the quarter ended March 31, 2018, prior to the open of the...

KMDA : 5.10 (-0.97%)
Kedrion Biopharma and Kamada Announce KEDRAB(R) (Rabies Immune Globulin [Human]) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

Kedrion Biopharma and Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), two leading human-derived protein therapeutics companies, announced today that KEDRAB(R) [Rabies Immune Globulin (Human)]...

KMDA : 5.10 (-0.97%)
Israel-based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US

Israeli startup Kanabo Research, which develops clinical solutions for extraction and vaporization of medical cannabis, announces it is entering an agreement with Constance Therapeutics, a US-based medical...

KMDA : 5.10 (-0.97%)
Israel-based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US

TEL AVIV, Israel , April 25, 2018 /PRNewswire/ -- Israeli startup Kanabo Research , which develops clinical solutions for extraction and vaporization of medical cannabis, announces it is entering...

KMDA : 5.10 (-0.97%)
Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Kamada Ltd. (the "Company") (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that the Company recently received feedback from the U.S. Food and Drug Administration...

KMDA : 5.10 (-0.97%)
Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017

-- Total Revenues for Fiscal 2017 were $102.8 Million, up 33% Over Fiscal 2016; Exceeded Full-Year Revenue Guidance of $100 Million

KMDA : 5.10 (-0.97%)
CollPlant Appoints David Tsur as Chairman of the Board

CollPlant (TASE: CLPT, OTC: CQPTY), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced...

KMDA : 5.10 (-0.97%)
Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Kamada's IV AAT Demonstrated Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment, Consistent with Previously Observed Results in Other Indications

KMDA : 5.10 (-0.97%)
Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease

Study will be Co-Funded by Mount Sinai and Kamada, and will Utilize Biomarkers Developed by Mount Sinai Acute GvHD International Consortium (MAGIC) to Identify Patients at High-Risk

KMDA : 5.10 (-0.97%)
Kamada Announces Nomination of Three New Members to its Board of Directors

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that the Company Board of Directors has nominated three new directors...

KMDA : 5.10 (-0.97%)
Kamada to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 13

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the third quarter ended September...

KMDA : 5.10 (-0.97%)
Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients

Efficacy trend was demonstrated in the pre-determined sub group of patients between the ages of 12 to 18, treated with the higher dose of 120mg/kg

KMDA : 5.10 (-0.97%)
Kamada Announces CFO Transition

Gil Efron, Deputy CEO and CFO, to Depart Kamada at End of Year;

ORPN : 1.97 (-1.50%)
KMDA : 5.10 (-0.97%)
Kamada to Present Corporate Overview at Two Investor Conferences in September

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that Amir London, Chief Executive Officer, will provide a corporate overview...

KMDA : 5.10 (-0.97%)
Kamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of Action

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today a collaboration for advanced research on Alpha-1 Antitrypsin (AAT) with...

KMDA : 5.10 (-0.97%)
Kamada Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the underwriters of its previously announced underwritten public...

KMDA : 5.10 (-0.97%)

Van Meerten Stock Picks

5 Great Large Caps
This morning I wanted to find 5 Large Cap stocks that had performed well over the last year and still appeared to have some juice left in them.
ABMD -0.44 , NFLX -1.77 , VLO +2.51 , RL +1.35 , ALGN +4.36
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures are trading 3 to 4 cents lower at the moment. They closed with most nearby contracts 1 to 2 cents lower on Friday, despite showing gains at midday. Front month July lost 4.37% on the week. Heavy rains are expected in much of the Corn Bel...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar